Compare KeyCorp (KEY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Sanofi SA — how do they compare? KeyCorp trades at $22.7 (market cap $24.32B), while Sanofi SA trades at $43.51 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 4.3× KeyCorp's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| KEY | SNY | |
|---|---|---|
Market Cap | $24.32B | $104.30B |
Sector | Financials | Health |
52-Week High | $23.99 | $52.34 |
52-Week Low | $16.78 | $41.33 |
Dividend Yield | 3.61% | 5.55% |
Enterprise Value | — | $124.19B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
